Replimune (REPL) Operating Leases (2018 - 2026)
Replimune (REPL) posted Operating Leases of $2.3 million for Q1 2026, down 37.54% sequentially from $3.7 million in Q4 2025, and down 24.32% YoY from $3.1 million in Q1 2025.
Analysis
Replimune (REPL) Operating Leases (2018 - 2026) Analysis & Trends
Replimune has reported Operating Leases for 9 years, with the latest figure at $2.3 million in Q1 2026.
- Quarterly Operating Leases fell 24.32% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (down 24.32% YoY) and the FY2026 annual result came in at $2.3 million, down 24.32% from the prior year.
- Operating Leases declined to $2.3 million in Q1 2026 per REPL's latest filing, from $3.7 million in the prior quarter.
- Over five years, Operating Leases peaked at $32.8 million in Q1 2022 and troughed at $2.3 million in Q1 2026.
- A 5-year average of $10.6 million and a median of $4.4 million in 2023 frame the typical range for Operating Leases.
- The widest YoY moves for Operating Leases: up 637.78% in 2023, down 86.63% in 2023.
- Over 5 years, Operating Leases stood at $4.3 million in 2022, then surged by 635.69% to $31.4 million in 2023, then slumped by 86.01% to $4.4 million in 2024, then retreated by 15.08% to $3.7 million in 2025, then tumbled by 37.54% to $2.3 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $2.3 million, $3.7 million, and $3.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Replimune | 1.46 Bn | 1.46 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.27 Mn |
| Mar 31, 2026 | 2.33 Mn |
| Dec 31, 2025 | 28.72 Mn |
| Sep 30, 2025 | 29.12 Mn |
| Jun 30, 2025 | 29.54 Mn |
| Mar 31, 2025 | 3.08 Mn |
| Dec 31, 2024 | 30.08 Mn |
| Sep 30, 2024 | 30.55 Mn |
| Jun 30, 2024 | 30.76 Mn |
| Mar 31, 2024 | 31.06 Mn |
| Dec 31, 2023 | 31.38 Mn |
| Sep 30, 2023 | 31.58 Mn |
| Jun 30, 2023 | 31.93 Mn |
| Mar 31, 2023 | 32.11 Mn |
| Dec 31, 2022 | 32.01 Mn |
| Sep 30, 2022 | 32.09 Mn |
| Jun 30, 2022 | 32.47 Mn |
| Mar 31, 2022 | 32.84 Mn |
| Dec 31, 2021 | 33.10 Mn |
| Sep 30, 2021 | 32.91 Mn |